非ST段抬高型心肌梗死患者普拉格雷预处理至冠状动脉造影的间隔时间分析
该研究为ACCOAST试验的预设分析,纳入4,001例非ST段抬高型心肌梗死患者,按普拉格雷预处理时长(随机化至造影时间)四分位分组,评估疗效与安全性终点。结果显示主要疗效终点及安全性终点在各四分位组间无差异,预处理时长与结局无交互作用。
要点
- 普拉格雷预处理时长四分位分组间主要疗效终点无差异(交互p=0.17)。
- 所有次要疗效终点不依赖于预处理时长。
- CABG或非CABG TIMI大出血在各四分位组间无差异(交互p=0.37)。
核心结论
- 在非ST段抬高型心肌梗死患者中,普拉格雷预处理时长增加各四分位组间出血风险 excess 和缺血获益缺失保持一致。
研究设计与样本
- ACCOAST试验的预设分析,4,033例随机患者中4,001例(99.2%)有预处理时长数据,按预处理时长四分位分组(0.1至2.5小时、2.5至3.9小时、3.9至13.6小时、>13.6小时)。
主要发现
- 主要疗效终点(心血管死亡、MI、卒中、紧急血运重建或GP IIb/IIIa抑制剂 bailout 使用)在各四分位组间无差异(交互p=0.17)。
- 次要疗效终点(包括心血管死亡、MI或卒中;全因死亡;支架血栓)均不依赖于预处理时长。
- 安全性终点(所有CABG或非CABG TIMI大出血)在各四分位组间无差异(交互p=0.37)。
临床怎么用
- 对于非ST段抬高型心肌梗死患者,延长普拉格雷预处理至造影的间隔时间并未带来缺血获益,且出血风险 excess 持续存在。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the ACCOAST (A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction) trial, the prasugrel pre-treatment strategy versus placebo was associated with excess bleeding complications and no improved ischemic outcome in non-ST-segment elevation myocardial infarction (MI). Whether patients with the longest pre-treatment duration had an ischemic benefit is unknown. OBJECTIVES: This pre-specified analysis of the ACCOAST trial aimed to assess the effect of pre-treatment duration with prasugrel (time from randomization to angiography) on outcomes. METHODS: Within the 4,033 patients randomized in the ACCOAST trial, pre-treatment duration was available in 4,001 patients (99.2%). The population of the trial was divided into quartiles of pre-treatment duration (0.1 to 2.5 h, 2.5 to 3.9 h, 3.9 to 13.6 h, and >13.6 h) with an evaluation of the primary efficacy endpoint of cardiovascular death, MI, stroke, urgent revascularization or glycoprotein IIb/IIIa inhibitor bailout use. Secondary efficacy outcomes including cardiovascular death, MI, or stroke; all-cause death; stent thrombosis and safety outcomes (all coronary artery bypass graft [CABG] or non-CABG TIMI [Thrombolysis In Myocardial Infarction] major bleeding) were also evaluated at 7 days. RESULTS: The primary efficacy outcome of cardiovascular death, MI, stroke, urgent revascularization or glycoprotein IIb/IIIa inhibitor bailout use did not differ between the quartiles of pre-treatment duration in the trial population (p = 0.17 for interaction). None of the secondary efficacy outcomes were found to be dependent on pre-treatment duration. The safety outcome of all CABG or non-CABG TIMI major bleeding did not differ between the quartiles of pre-treatment duration (p = 0.37 for interaction). CONCLUSIONS: In non-ST-segment elevation MI patients, the excess risk of bleeding and the absence of ischemic benefit were consistent across the quartiles of increasing duration of prasugrel pre-treatment. (A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction [ACCOAST]; NCT01015287).
引用
- Silvain J, Rakowski T, Lattuca B, et al. Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2019. PMID: 30819358. doi:10.1016/j.jacc.2018.11.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。